Island Pharmaceuticals Ltd (AU:ILA) has released an update.
Island Pharmaceuticals Ltd is advancing the clinical development of ISLA-101, their flagship antiviral drug for dengue fever, with a Phase 2 clinical trial expected to start in August 2024 after FDA protocol review. The company has streamlined the study design, now focusing on a single dose level and expanding the trial to include both preventative and therapeutic approaches. Excitement builds as the company also considers acquiring galidesivir, another promising antiviral drug, with further discussions planned at the upcoming Bioshares Conference.
For further insights into AU:ILA stock, check out TipRanks’ Stock Analysis page.
